deferoxamine has been researched along with vitamin d 2 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Aloia, J; Yeh, JK; Zaino, EC | 1 |
| Aloia, JF; Ostuni, JA; Yeh, JK; Zaino, EC | 1 |
1 review(s) available for deferoxamine and vitamin d 2
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for deferoxamine and vitamin d 2
| Article | Year |
|---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Defective vitamin D metabolism in thalassemia major.
Topics: Adolescent; Adult; Calcitriol; Calcium; Chelating Agents; Child; Child, Preschool; Deferoxamine; Ergocalciferols; Female; Humans; Hydroxyproline; Iron; Liver; Male; Parathyroid Hormone; Phosphorus; Thalassemia; Vitamin D | 1985 |
Combined vitamin D parathyroid defect in thalassemia major.
Topics: 25-Hydroxyvitamin D 2; Adolescent; Adult; Child; Deferoxamine; Ergocalciferols; Female; Humans; Hypoparathyroidism; Male; Thalassemia | 1982 |